The Panova 3 trial proved TTFields' benefit with a gemcitabine-based chemotherapy. However, with up to 50% of patients receiving the FOLFIRINOX regimen, it is unknown if TTFields provide the same survival benefit when combined with this common alternative, representing a critical evidence gap for clinicians.

RASONQ's label allows its use as a first-line treatment for pancreatic cancer patients ineligible for chemotherapy. This will likely drive its use earlier in treatment, complicating the design and enrollment of future clinical trials for competing drugs in both first- and second-line settings.

Beyond improving survival in metastatic disease, clinicians leverage liposomal irinotecan's high tumor shrinkage rate to make borderline resectable or locally advanced pancreatic cancer patients eligible for curative surgery. This strategic use aims to increase the small percentage of patients who can achieve a cure.

The FDA-approved Optune device, which uses tumor-treating fields, significantly improved median overall survival and pain-free survival for patients with locally advanced, unresectable pancreatic cancer when added to chemotherapy, offering a new non-invasive treatment option.

Despite pancreatic cancer being notoriously difficult, Actuate prioritized it as a lead indication for strategic reasons. Strong preclinical data allowed the company to bypass later-line trials and move directly into a first-line setting, a 'leapfrog' maneuver that significantly accelerates the drug's overall development and regulatory path.

A key future goal in GI oncology is for systemic drugs to become so effective in early disease stages that they diminish or eliminate the need for surgery and radiation. This would spare patients from life-changing procedures like organ removal for gastric, rectal, and pancreatic cancers.

Unlike systemic treatments, which rarely cause pancreatic tumors to shrink on scans, TAMP is demonstrating meaningful radiographic responses. This includes resolving major vessel narrowing, suggesting a more potent local effect and hinting at its potential for converting patients to resectability.

The future of treating advanced pancreatic cancer involves innovative, localized approaches beyond systemic chemotherapy. These include phototherapy to destroy tumor tissue around key blood vessels and transarterial perfusion for direct chemotherapy delivery, aiming to make more patients operable and improve outcomes.

The mechanism of Tumor-Treating Fields extends beyond direct cell killing. It gently controls cancer by altering the tumor's microenvironment and overall biology to be more favorable. This not only controls tumor growth but can also contribute to symptomatic relief for the patient.